title: Effects of acute K-strophantidin administration on left ventricular relaxation and filling phase in coronary artery disease.
abstract: In 10 patients with coronary artery disease, preserved left ventricular (LV) performance and absence of previous myocardial infarction, the effects of an acute intravenous administration of k-strophantidin (0.005 mg/kg over 10 minutes) on selected parameters of both LV systolic and diastolic function, including relaxation, were evaluated. An increase in positive first derivative of LV pressure (dP/dt) and in the ratio between dP/dt and the pressure developed (dP/dt/P) (1,530 +/- 287) 1,600 +/- 329 mm Hg/s [p less than 0.05], and 30 +/- 6 to 34 +/- 8 s-1 [p less than 0.05], respectively) demonstrated the inotropic effect of k-strophantidin, whereas volumetric parameters of systolic function (end-systolic and stroke volume indexes, and ejection fraction) did not show any significant change. However, LV relaxation was impaired by k-strophantidin injection; in fact, mean values of T constant were significantly increased from 50 +/- 12 to 55 +/- 13 ms (p less than 0.01). Lowest LV and end-diastolic pressures increased from 8 +/- 4 to 11 +/- 4 mm Hg (p less than 0.05) and from 17 +/- 6 to 20 +/- 8 mm Hg (p less than 0.05), respectively. The end-diastolic volume and maximal rate of volumetric increase during the early and late filling phases were not modified by k-strophantidin. Mean aortic pressure increased from 110 +/- 10 to 120 +/- 12 mm Hg (p less than 0.001). Therefore, in patients with coronary artery disease and LV preserved performance, an acute intravenous administration of k-strophantidin appears to stimulate contractility and to worsen relaxation, and minimal LV and end-diastolic pressures.
authors.affiliation: Cattedra di Cardiologia, Università degli Studi di Parma e Brescia, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Bolognesi
authors.forename: F
authors.initials: F
authors.lastname: Cucchini
authors.forename: A
authors.initials: A
authors.lastname: Javernaro
authors.forename: R
authors.initials: R
authors.lastname: Zeppellini
authors.forename: C
authors.initials: C
authors.lastname: Manca
authors.forename: O
authors.initials: O
authors.lastname: Visioli
mesh_terms: D000368:Aged; D003327:Coronary Disease / Q000503:physiopathology*; D003971:Diastole / Q000187:drug effects*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013328:Strophanthins / Q000008:administration & dosage / Q000494:pharmacology*; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D013328:Strophanthins; C029082:strophanthin K